Kaye, Frederic J.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 9,368

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature

Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities

Cited by 4,017

Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

Sellers, W. R., Novitch, B. G., Miyake, S., Heith, A., Otterson, G. A., Kaye, F. J., Lassar, A. B., & Kaelin, W. G. (1998) · Genes & Development

Cancer-related Molecular PathwaysChromatin Remodeling and Cancer

Cited by 343

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer

Kaye, F. J. (2002) · Oncogene

Cancer-related Molecular PathwaysLung Cancer Research Studies

Cited by 153

PROTAC therapy as a new targeted therapy for lung cancer

Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy

Protein Degradation and InhibitorsLung Cancer Treatments and Mutations

Cited by 87

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., et al. (2022) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 62

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors

François, R. A., Maeng, K., Nawab, A., Kaye, F. J., Hochwald, S. N., & Zajac-Kaye, M. (2015) · Journal of the National Cancer Institute

Neuroendocrine Tumor Research AdvancesPI3K/AKT/mTOR signaling in cancer

Cited by 48

A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.

Gopalan, P. K., Pinder, M. C., Chiappori, A., Ivey, A. M., Gordillo Villegas, A., & Kaye, F. J. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 47